Issuance of Final ICO Regulations in the Philippines Postponed by Market Regulator

tlmfoundationcosmetics.com
Medtronic plc (NYSE: MDT ) disclosed that the FDA has given its approval of the Enlite sensor for use with iPro2 Professional Continuous Glucose Monitoring (CGM) system. This is a market-leading CGM system, which allows healthcare providers to get a clear picture of glucose control for the diabetes patients they treat. The medical device maker said that the Enlite sensor is a disposable glucose sensor, which could be worn up to six days providing better comfort to the patients. Medtronics VP and GM for Non-Intensive Diabetes Therapies, Laura Stoltenberg, said, We fundamentally believe that to improve outcomes for people with diabetes, physicians need advanced insights to optimize therapy and people with diabetes need to understand the context behind glucose fluctuations to drive behavior change. The company indicated that the iPro2 Professional CGM system records a patients glucose levels 24 hours a day for a maximum of six days. The iPro2 system offers physicians with insights into the nutrition plan, medication regimen and daily activities that affect glucose levels of people with diabetes. On Thursday, the stock shed $0.08, or 0.09 percent, to $86.95. See more from Benzinga Medtronic Gets First-Ever FDA Approval For Cement-Augmented Pedicle Screws Medtronic Introduces Revamped Minimally Invasive Spine Fusion Procedures Medtronic Gets FDA Approval For IN.PACT Admiral DCB 150 mm Lengths © 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. View comments
Harnessing Emotional Intelligence for Personal Growth
Explore 15 effective strategies to enhance your emotional intelligence for better relationships and personal growth.